Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 11/20 | 0.53 |
| ▸ | MC1R | Q01726 | 11/20 | 0.53 |
| ▸ | MC5R | P33032 | 4/20 | 0.49 |
| ▸ | MC3R | P41968 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392475 | 1.00 | MC4R (0.53) | MC4RMC1RMC5RMC3R | |
| SCHEMBL21392443 | 0.97 | MC4R (0.51) | MC4RMC1RMC5RMC3R | |
| SCHEMBL12092513 | 0.97 | MC4R (0.51) | MC4RMC1RMC5RMC3R | |
| SCHEMBL20206209 | 0.97 | MC4R (0.51) | MC4RMC1RMC5RMC3R | |
| SCHEMBL21392471 | 0.96 | MC4R (0.50) | MC4RMC1RMC5RMC3R | |
| SCHEMBL20362983 | 0.93 | MC4R (0.53) | MC4RMC1RMC5RMC3R | |
| SCHEMBL21392395 | 0.93 | MC4R (0.52) | MC4RMC1RMC5RMC3R | |
| SCHEMBL20206236 | 0.93 | MC4R (0.52) | MC4RMC1RMC5RMC3R | |
| SCHEMBL12092693 | 0.93 | MC4R (0.52) | MC4RMC1RMC5RMC3R | |
| SCHEMBL21392393 | 0.93 | MC4R (0.52) | MC4RMC1RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | PALATIN TECHNOLOGIES, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | PALATIN TECHNOLOGIES INC (US) | 2020-10-29 | — | — | US | disclosed |
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | PALATIN TECHNOLOGIES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2019183472-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDE FORMULATIONS AND METHODS FOR GASTROINTESTINAL TRACT-SPECIFIC DELIVERY | PALATIN TECHNOLOGIES, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-10017539-B2 | Melanocortin-1 receptor-specific cyclic hexapeptides | PALATIN TECHNOLOGIES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | PALATIN TECHNOLOGIES INC (US) | 2018-05-31 | — | — | US | disclosed |
| US-20170008931-A1 | Melanocortin-1 Receptor-Specific Cyclic Hexapeptides | PALATIN TECHNOLOGIES INC (US) | 2017-01-12 | — | — | US | disclosed |
| US-9447148-B2 | Melanocortin-1 receptor-specific cyclic peptides | PALATIN TECHNOLOGIES, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150038434-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES INC (US) | 2015-02-05 | — | — | US | disclosed |
| US-8877890-B2 | Melanocortin-1 receptor-specific cyclic peptides | PALATIN TECHNOLOGIES, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130296256-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-8492517-B2 | Melanocortin-1 receptor-specific cyclic peptides | PALATIN TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120225828-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | PALATIN TECHNOLOGIES, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2011063366-A1 | MELANOCORTIN-1 RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885MC1R 1/4885MC5R 4/4885 |
| US-11286280-B2 | Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy | MC3R, MC1R, MC2R | MC4R 6/4885MC1R 2/4885MC5R 7/4885 |
| US-10017539-B2 | Melanocortin-1 receptor-specific cyclic hexapeptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885MC5R 3/4885 |
| US-20120225828-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885MC5R 3/4885 |
| US-20150038434-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885MC5R 3/4885 |
| US-20200339631-A1 | Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy | MC3R, MC1R, MC2R | MC4R 6/4885MC1R 2/4885MC5R 7/4885 |
| US-20170008931-A1 | Melanocortin-1 Receptor-Specific Cyclic Hexapeptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885MC5R 3/4885 |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885MC1R 1/4885MC5R 4/4885 |
| US-20130296256-A1 | Melanocortin-1 Receptor-Specific Cyclic Peptides | MC1R, MC3R, MC5R | MC4R 4/4885MC1R 1/4885MC5R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.